Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant chimeric COVID-19 epitope DC vaccine study in COVID-19
ChiCTR2000030750Phase 2Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Mar 2020
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant chimeric COVID-19 epitope DC vaccine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoints: Shorten the duration of the disease, Antipyretic rate and 10 more. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
recombinant chimeric COVID-19 epitope DC vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030750.